S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Abeona Therapeutics Inc. (ABEO)
Chart Events
Performance Outlook
| Previous Close | 0.1695 |
| Open | 0.1700 |
| Bid | 0.1577 x 2200 |
| Ask | 0.1699 x 1100 |
| Day's Range | 0.1535 - 0.1800 |
| 52 Week Range | 0.1300 - 1.9200 |
| Volume | |
| Avg. Volume | 2,053,028 |
| Market Cap | 22.872M |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5670 |
| Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.67 |
- Zacks
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
- Zacks
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
- GlobeNewswire
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market und
